GlobeNewswire

GAMCO International SICAV Announces the Launch of a new UCITS sub-fund: GAMCO Convertible Securities

Share

RYE, N.Y., Jan. 11, 2021 (GLOBE NEWSWIRE) -- GAMCO Investors, Inc. (NYSE:GBL) announced today that GAMCO International SICAV (Luxembourg), managed by Gabelli Funds, launched a new sub-fund, GAMCO Convertible Securities.

GAMCO Convertible Securities’ objective is to seek to provide current income as well as long term capital appreciation through a total return strategy by investing in a diversified portfolio of global convertible securities.

The Fund leverages the firm’s history of investing in dedicated convertible security portfolios since 1979. Multiple share classes will be available at launch and are tailored for Global institutional investors as well as select non-US retail investors. At the onset, the Fund will launch with an institutional founder’s class at a reduced fee.

Michael Gabelli, Managing Director and Director of Global Business Development for Gabelli noted, “The GAMCO Convertible Securities fund offers investors access to one of Gabelli’s core strategies within a UCITS compliant structure, providing daily liquidity via accumulating share classes and a distributing class. We are excited to bring an actively managed fund to the European and Global marketplace that will be dedicated to global convertible securities while factoring in ESG guidelines.”

Also commenting on the launch, Thomas Dinsmore, Co-Portfolio Manager said, “We are delighted to apply our combined 60+ years of convertible portfolio management experience to this new offering affording investors across the globe access to our active approach to converts. The convertible markets continue to provide a strong flow of new issuances as well as attractive investment opportunities.”

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The prospectus contains information about these and other matters and should be read carefully before investing. To obtain a prospectus, call +1-914-921-5135 or visit www.gabelli.com/sicav.

NO REGISTRATION STATEMENT HAS BEEN FILED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE “SEC”) OR ANY STATE SECURITIES AUTHORITY WITH RESPECT TO THIS OFFERING. THE SHARES OF THE FUND HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1933 (THE “ACT”). THE SHARES MAY ONLY BE OFFERED AND SOLD IN OFFSHORE TRANSACTIONS (AS DEFINED IN REGULATION S UNDER THE ACT) TO NON - U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE ACT).

SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION

Our disclosure and analysis in this press release contain some forward-looking statements. Forward-looking statements give our current expectations or forecasts of future events. Such statements are subject to contingencies and uncertainties, some or all of which may be material. We direct your attention to the cautionary statements regarding forward-looking information set forth in documents on Gabelli’s website. We do not undertake to update publicly any forward-looking statements if we subsequently learn that we are unlikely to achieve our expectations or if we receive any additional information relating to the subject matters of our forward-looking statements.

Contact:Michael M. Gabelli
Managing Director
+1 (914) 921-5135
+44 (0)20 3206 2100
www.gabelli.com/sicav

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

REPURCHASE OF SHARES20.1.2021 18:15:00 CETPress release

REPURCHASE OF SHARES Amsterdam, the Netherlands - Flow Traders N.V. (“Flow Traders”) (Euronext: FLOW) has repurchased 62,790 of its own shares in the period from 14 January 2021 up to and including 20 January 2021 at an average price of €28.52. As announced on 11 November 2020, these repurchases are being made in order to satisfy the requirements of various employee incentive plans. The consideration of this purchase was €1.8 million. The total number of shares purchased under this programme to date is 799,922 shares at an average price of €26.90 for a total consideration of €21.5 million. 2,031,091 shares were held in treasury as at 20 January 2021. Contact Details Flow Traders N.V. Jonathan Berger / Investor Relations Officer Phone: +31 20 7996799 Email: investor.relations@flowtraders.com About Flow Traders Flow Traders is a leading global financial technology-enabled liquidity provider in financial products, historically specialized in Exchange Traded Products (ETPs), now expanding

KONNECT SELECTS SOLUTIONS 30 TO ROLL OUT ITS OFFER IN WESTERN EUROPE20.1.2021 18:00:00 CETPress release

Solutions 30 (Euronext Paris: S30) has been selected by konnect, an entity of the Eutelsat Group (Euronext Paris: ETL), to roll out its new ultra high-speed satellite Internet access for the general public. As part of this partnership, Solutions 30 will carry out all installation services, allowing konnect to guarantee its customers a professional, uniform, and standardized installation in European countries where its offer is marketed. Europe’s leading provider of rapid-response multi-technology services, Solutions 30 performs more than 60,000 call-outs a day thanks to a team of 11,000 technicians and a particularly dense territorial network in Europe. For more than 15 years, the company has leveraged a unique software platform for team management and call-out optimization to provide customers with a standardized operating process that guarantees service quality and consistency. A significant part of Solutions 30’s business is in telecommunications, where it intervenes on behalf of th

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING20.1.2021 16:20:00 CETPress release

Bid date, 2021-01-22Bid Submission Date2021-01-22Bid times10.30-11.00 (CET/CEST) on the Bid dateOffered Amount50 billion SEKMaximum Permitted Bid Volume12.5 billion SEK from an individual bidderSettlement Date2021-01-26Minimum Permitted Bid Volume10 million SEK per bidFinal Repayment Date2025-01-27Maximum Allocation25 per cent of Offered AmountAllocation TimeNo later than 11.30 (CET/CEST) on the Bid dateRepayment Date2022-01-26Option Repayment Date 12023-01-26Option Repayment Date 22024-01-26Interest rateThe Riksbank´s applicable repo rateAdditional interest rate0.10 per centConfirmation of bids to e-maileol@riksbank.se Stockholm, 2021-01-20 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes20.1.2021 16:07:55 CETPress release

Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the US in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. The submission follows the application on 29 December 2020 for label extension to the European Medicines Agency (EMA). The submission is based on the results from the SUSTAIN FORTE trial, which included 961 people with type 2 diabetes in need of treatment intensification. In the trial, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c compared to semaglutide 1.0 mg. In the tria

ArcAroma AB: 210120 ArcAroma och OptiFreeze skapar tillsammans ett starkare bolag20.1.2021 16:00:00 CETPressemelding

Pressmeddelande 2021-01-20 ArcAroma och OptiFreeze skapar tillsammans ett starkare bolag Styrelserna i ArcAroma AB (publ) och OptiFreeze AB (publ) beslutade igår att föreslå ett samgående mellan bolagen genom fusion. Beslutet har tagits mot bakgrund av den marknadspotential och de synergieffekter som identifierats i samband med bolagens utökade samarbetsavtal, som tecknades i november 2020. ArcAroma och OptiFreeze har i olika omfattning samarbetat sedan grundandet av OptiFreeze 2011, där ArcAroma var en av grundarna till OptiFreeze. Sedan bolagens utökade samarbete inleddes i november 2020 har marknadsmöjligheter och synergier framstått som allt tydligare om bolagens resurser och tillväxtpotential kombineras. När fusionen är genomförd är målet att inleda processen för ett listbyte till Nasdaq Stockholm Small Cap. Storleken på det fusionerade bolaget skapar rätt förutsättningar för en kostnadseffektiv accelererad tillväxt som vilar på en unik teknologiplattform. Det nya bolagets kostnad

Equinor ASA: Early Warning Press Release20.1.2021 12:49:07 CETPress release

Stavanger, Rogaland, Norway, January 20, 2021 – Equinor ASA ("Equinor") (OSE: EQNR, NYSE: EQNR) announces that on January 19, 2021 it disposed of its beneficial ownership of an aggregate of 100,000,000 common shares ("Common Shares") of Athabasca Oil Corporation ("Athabasca"), at a price of C$0.18 per Common Shares, for aggregate gross proceeds of C$18,000,000 (the "Transaction"), through the facilities of the Toronto Stock Exchange on a block trade basis. Immediately prior to the Transaction, Equinor beneficially owned and controlled a total of 100,000,000 Common Shares of Athabasca, representing approximately 18.8% of the issued and outstanding Common Shares of Athabasca. Immediately following the Transaction, Equinor no longer has beneficial ownership and control over any of the issued and outstanding Common Shares of Athabasca. As a result of the Transaction, Equinor's beneficial ownership of Common Shares of Athabasca has decreased to less than 10% of the issued and outstanding Co